title: Effects of pirenzepine on omeprazole-induced hypergastrinemia and acid suppression in peptic ulcer patients.
abstract: Omeprazole effectively suppresses acid secretion, resulting in the long-term elevation of intragastric pH and serum gastrin level. Pirenzepine has been reported to inhibit gastrin secretion. This study was carried out to examine the effects of additional pirenzepine treatment on the hypergastrinemia and gastric acid suppression induced by omeprazole. Concentrations of serum gastrin and plasma somatostatin were measured in 28 peptic ulcer patients before treatment, after omeprazole treatment (20 mg/day) for 2 weeks, and after omeprazole and pirenzepine (100 mg/day) treatment for 2 weeks. The acid inhibitory effect of pirenzepine treatment in addition to omeprazole was evaluated by 24-h intragastric pH measurement in six healthy volunteers. Serum gastrin level was increased significantly, to 2.4-fold the pretreatment level, by omeprazole treatment. Additional treatment with pirenzepine suppressed serum gastrin level to 0.6-fold the omeprazole-treatment level. The serum somatostatin level was not altered significantly either by omeprazole treatment or by omeprazole and pirenzepine treatment. In healthy volunteers whose pH 3 holding time on 24-h intragastric pH monitoring was 70% by omeprazole treatment, omeprazole and pirenzepine treatment markedly increased the pH 3 holding time, to 89%. These findings suggest that pirenzepine is useful in reducing the undesirable effects of omeprazole-induced hypergastrinemia, i.e., the excessive trophic effect of omeprazole on the acid-secreting part of the stomach and the overstimulation of acid secretion. The additional pirenzepine treatment is also effective in suppressing acid secretion.
authors.affiliation: Department of Internal Medicine, Hiroshima Red Cross Hospital, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Tari
authors.forename: M
authors.initials: M
authors.lastname: Hamada
authors.forename: T
authors.initials: T
authors.lastname: Kamiyasu
authors.forename: Y
authors.initials: Y
authors.lastname: Fukino
authors.forename: M
authors.initials: M
authors.lastname: Sumii
authors.forename: K
authors.initials: K
authors.lastname: Haruma
authors.forename: K
authors.initials: K
authors.lastname: Sumii
authors.forename: M
authors.initials: M
authors.lastname: Inoue
authors.forename: G
authors.initials: G
authors.lastname: Kajiyama
mesh_terms: D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005755:Gastrins / Q000097:blood*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000378:metabolism; D010890:Pirenzepine / Q000627:therapeutic use*; D011863:Radioimmunoassay; D013004:Somatostatin / Q000097:blood; D013276:Stomach Ulcer / Q000188:drug therapy / Q000378:metabolism
chemical_list: D000897:Anti-Ulcer Agents; D005755:Gastrins; D010890:Pirenzepine; D013004:Somatostatin; D009853:Omeprazole